All 1 tracked stories fall under one category: clinical-trial. Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal) is most often covered alongside Dr. Marc Siegel, which appears in 1 of these 1 story. Each carries 2 original sources on average.
Figures are computed live from our source-verified story record
— see our methodology for how impact and
sentiment are derived.
What the coverage shows about Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal)
All 1 tracked stories fall under one category: clinical-trial. Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal) is most often covered alongside Dr. Marc Siegel, which appears in 1 of these 1 story. Each carries 2 original sources on average. We currently track 1 Cross-Sector story that mention Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal), all published on August 18, 2026.
Stories tracked
1
Sources per story
2
Computed from the 1 stories linked to this entity. Beat comparisons are omitted because no baseline was available for this window.
Coverage cohort
Appears alongside
Other entities that clear the same relevance threshold in stories also covering Early-stage solid tumors (breast, colon, lung, pancreatic, stomach, esophageal). Shared-story counts are live from our verified record — not editorial picks.
Diagnosis-to-treatment intervals grew for six early-stage cancers from 2012–2023, with lung (+12 days) and stomach (+14 days) leading. For biopharma, longer real-world waits threaten neoadjuvant therapy windows and perioperative trial design.